Agenda item 2 is consideration of our approach to the financial memorandum to the Human Tissue (Scotland) Bill, which was introduced on 3 June 2005. The Health Committee is the lead committee on the bill. The clerks have produced a paper that sets out the bill's anticipated costs. The recommendation is that we adopt level 1 scrutiny for the bill, which is our minimum level of scrutiny for a financial memorandum. Are members content with that approach?